tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2021 Feb 1;8(2)
fab050.
doi: 10.1093/ofid/ofab050. eCollection 2021 Feb.
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
David Seftel[SUP] 1 2 [/SUP], David R Boulware[SUP] 3 [/SUP]
Affiliations
Abstract
We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.
Keywords: COVID-19; SARS-COV-2; cohort; coronavirus; fluvoxamine.
. 2021 Feb 1;8(2)
fab050.doi: 10.1093/ofid/ofab050. eCollection 2021 Feb.
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
David Seftel[SUP] 1 2 [/SUP], David R Boulware[SUP] 3 [/SUP]
Affiliations
- PMID: 33623808
- PMCID: PMC7888564
- DOI: 10.1093/ofid/ofab050
Abstract
We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.
Keywords: COVID-19; SARS-COV-2; cohort; coronavirus; fluvoxamine.